約70%的上皮性卵巢癌患者確診時已屬晚期。當無法進行初次最佳手術時，新輔助化療後進行中間減瘤手術是其中一種治療選擇。然而，對於手術的最佳時機並無共識。CA125是卵巢癌中眾所周知的腫瘤標記。

適應症：Ovarian Cancer、Fallopian Tube Cancer、Peritoneal Cancer

收案條件

Patients must be at least 18 years old.
Patients who have Eastern Cooperative Oncology Group (ECOG) score 0-1.
Patients who are competent to give informed consent.
Patients who have stage III-IV histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube or primary peritoneal cancer not amenable for primary debulking surgery (PDS).
Patients who are planned for neoadjuvant chemotherapy (NACT) using platinum-based chemotherapy +/- bevacizumab or biosimilar. Those who are receiving NACT before interval debulking surgery (IDS) are also eligible.
Patients who have an evaluable CA125 level at baseline (i.e., baseline level is at least 2x upper limit of normal).
Patients who have baseline computed tomography of at least abdomen and pelvis, or positron emission tomography (PET)-CT. Magnetic resonance imaging (MRI) is also acceptable but the same modality has to be used when assessing the feasibility of IDS.
Patients who agree to undergo IDS, where the time of IDS may differ from the usual clinical practice.
Patients who agree to receive adjuvant chemotherapy, if clinically indicated. The total number of chemotherapy should be at least four or above.

Patients who have borderline malignancy, or non-epithelial ovarian cancer like germ cell or sex cord tumor, or metastatic diseases from other origins like Krukenberg's tumor
Patients who are eligible for PDS
Patients who are not fit for PDS because of medical morbidities or refusal of operation
Patients who have already started NACT outside the study centres, except those who have just had one cycle within 21 days and the baseline CA125 is available.
Patients who are pregnant

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

晚期卵巢癌中間減瘤手術的個人化時機